Limited Toxicity of Prolonged Therapy with High Doses of Amphotericin B Lipid Complex
| Autor: | Mark W. Kline, Leonard Fieber, Tom A. Larsen, Ronald Fishbach, Patrick O. Tennican, Richard L. Harris, Edward N. Janoff, Susan Kline, Martha Greenwood |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male Microbiology (medical) Drug Antifungal Agents Time Factors Adolescent media_common.quotation_subject medicine.medical_treatment Hypokalemia Pharmacology Kidney Dosage form chemistry.chemical_compound Amphotericin B Humans Medicine Child media_common Creatinine Chemotherapy business.industry Drug Tolerance Middle Aged Lipids Discontinuation Infectious Diseases Mycoses chemistry Toxicity Potassium Female business Amphotericin B-Lipid Complex medicine.drug |
| Zdroj: | Clinical Infectious Diseases. 21:1154-1158 |
| ISSN: | 1537-6591 1058-4838 |
| Popis: | We describe six patients with invasive fungal infections who received large cumulative doses (22.3-73.6 g) of amphotericin B lipid complex (ABLC) over 21-121 weeks. The drug was well tolerated at these very large doses, and there was limited toxicity. Collectively, these patients received ABLC therapy for a mean of 53.8 weeks (range, 21-121 weeks). The mean serum creatinine level at the start of ABLC therapy was 1 mg/dL (range, 0.4-1.9 mg/dL), and at the end of therapy this level was 1.5 mg/dL (range, 1.0-2.0 mg/dL). Over the course of therapy, only two patients had serum creatinine levels of > or = 2 mg/dL, with transient peak serum creatinine levels of 3.5 and 2.8 mg/dL, respectively. Several patients required replacement therapy with oral or intravenous potassium. None of the patients had ABLC-associated toxic effects necessitating discontinuation of the treatment. ABLC may be given in substantially larger doses than conventional amphotericin B, and very high doses of ABLC that are administered over several months appear to be relatively less toxic than those of conventional amphotericin B. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|